Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients with Type 2 Diabetes in the Asia-Pacific Region

30 April 2021


Lee-Ling Lim, Eric S H Lau, Amy WC Fu, Subir Ray, Yi-Jen Hung, Alexander TB Tan, Parinya Chamnan, Wayne HH Sheu, Manoj S Chawla, Yook-Chin Chia, Lee-Ming Chuang, Duc-Cong Nguyen, Aravind Sosale, Banshi D Saboo, Uday Phadke, Jothydev Kesavadev, Su-Yen Goh, Neeru Gera, Thi Thanh Huyen Vu, Ronald CW Ma, Vanessa Lau , Andrea OY Luk, Alice PS Kong, Juliana CN Chan, Asia-Pacific JADE Study Group

DOWNLOAD FULL PDF VIEW RESEARCH HERE
COPY CITATION
Copied!

Abstract

Importance

Many health care systems lack the efficiency, preparedness, or resources needed to address the increasing number of patients with type 2 diabetes, especially in low- and middle-income countries.

Objective

To examine the effects of a quality improvement intervention comprising information and communications technology and contact with nonphysician personnel on the care and cardiometabolic risk factors of patients with type 2 diabetes in 8 Asia-Pacific countries.

Design, Setting, and Participants

This 12-month multinational open-label randomized clinical trial was conducted from June 28, 2012, to April 28, 2016, at 50 primary care or hospital-based diabetes centers in 8 Asia-Pacific countries (India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam). Six countries were low and middle income, and 2 countries were high income. The study was conducted in 2 phases; phase 1 enrolled 7537 participants, and phase 2 enrolled 13 297 participants. Participants in both phases were randomized on a 1:1 ratio to intervention or control groups. Data were analyzed by intention to treat and per protocol from July 3, 2019, to July 21, 2020.

Interventions

In both phases, the intervention group received 3 care components: a nurse-led Joint Asia Diabetes Evaluation (JADE) technology-guided structured evaluation, automated personalized reports to encourage patient empowerment, and 2 or more telephone or face-to-face contacts by nurses to increase patient engagement. In phase 1, the control group received the JADE technology–guided structured evaluation and automated personalized reports. In phase 2, the control group received the JADE technology–guided structured evaluation only.

Main Outcomes and Measures

The primary outcome was the incidence of a composite of diabetes-associated end points, including cardiovascular disease, chronic kidney disease, visual impairment or eye surgery, lower extremity amputation or foot ulcers requiring hospitalization, all-site cancers, and death. The secondary outcomes were the attainment of 2 or more primary diabetes-associated targets (glycated hemoglobin A1c <7.0%, blood pressure <130/80 mm Hg, and low-density lipoprotein cholesterol <100 mg/dL) and/or 2 or more key performance indices (reduction in glycated hemoglobin A1c≥0.5%, reduction in systolic blood pressure ≥5 mm Hg, reduction in low-density lipoprotein cholesterol ≥19 mg/dL, and reduction in body weight ≥3.0%).

Results

A total of 20 834 patients with type 2 diabetes were randomized in phases 1 and 2. In phase 1, 7537 participants (mean [SD] age, 60.0 [11.3] years; 3914 men [51.9%]; 4855 patients [64.4%] from low- and middle-income countries) were randomized, with 3732 patients allocated to the intervention group and 3805 patients allocated to the control group. In phase 2, 13 297 participants (mean [SD] age, 54.0 [11.1] years; 7754 men [58.3%]; 13 297 patients [100%] from low- and middle-income countries) were randomized, with 6645 patients allocated to the intervention group and 6652 patients allocated to the control group. In phase 1, compared with the control group, the intervention group had a similar risk of experiencing any of the primary outcomes (odds ratio [OR], 0.94; 95% CI, 0.74-1.21) but had an increased likelihood of attaining 2 or more primary targets (OR, 1.34; 95% CI, 1.21-1.49) and 2 or more key performance indices (OR, 1.18; 95% CI, 1.04-1.34). In phase 2, the intervention group also had a similar risk of experiencing any of the primary outcomes (OR, 1.02; 95% CI, 0.83-1.25) and had a greater likelihood of attaining 2 or more primary targets (OR, 1.25; 95% CI, 1.14-1.37) and 2 or more key performance indices (OR, 1.50; 95% CI, 1.33-1.68) compared with the control group. For attainment of 2 or more primary targets, larger effects were observed among patients in low- and middle-income countries (OR, 1.50; 95% CI, 1.29-1.74) compared with high-income countries (OR, 1.20; 95% CI, 1.03-1.39) (P = .04).

Conclusions and Relevance

In this 12-month clinical trial, the use of information and communications technology and nurses to empower and engage patients did not change the number of clinical events but did reduce cardiometabolic risk factors among patients with type 2 diabetes, especially those in low- and middle-income countries in the Asia-Pacific region.

Reference

  1. Penm, J., MacKinnon, N. J., Strakowski, S. M., Ying, J., & Doty, M. M. (2017). Minding the gap: Factors associated with primary care coordination of adults in 11 countries. Annals of Family Medicine, 15(2), 113–119. https://doi.org/10.1370/afm.2028
  2. Manne-Goehler, J., Geldsetzer, P., Agoudavi, K., Andall-Brereton, G., Aryal, K. K., Bicaba, B. W., Bovet, P., Brian, G., Dorobantu, M., Gathecha, G., Gurung, M. S., Guwatudde, D., Msaidié, M., Houehanou, C., Houinato, D., Kond表, M., Labadarios, D., Martins, J. S., Mayige, M. T., ... Atun, R. (2019). Health system performance for people with diabetes in 28 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Medicine, 16(3), Article e1002751. https://doi.org/10.1371/journal.pmed.1002751
  3. GBD 2016 Healthcare Access and Quality Collaborators. (2018). Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease study 2016. The Lancet, 391(10136), 2236–2271. https://doi.org/10.1016/S0140-6736(18)30994-2
  4. Lim, L. L., Lau, E. S. H., Kong, A. P. S., Davies, M. J., Levitt, N. S., Eliasson, B., Aguilar-Salinas, C. A., Ning, G., So, W. Y., Chan, J. C. N., & Luk, A. O. Y. (2018). Aspects of multicomponent integrated care promote sustained improvement in surrogate clinical outcomes: A systematic review and meta-analysis. Diabetes Care, 41(6), 1312–1320. https://doi.org/10.2337/dc17-2010
  5. Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Danesh, J., & Emerging Risk Factors Collaboration. (2015). Association of cardiometabolic multimorbidity with mortality. JAMA, 314(1), 52–60. https://doi.org/10.1001/jama.2015.7008
  6. Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A. M., Zethelius, B., Miftaraj, M., McGuire, D. K., Wallentin, L., & Gudbjörnsdottir, S. (2018). Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 379(7), 633–644. https://doi.org/10.1056/NEJMoa1800256
  7. Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, Y., Ohashi, K., Hara, K., Morise, A., Izumi, K., Ishizuka, N., Ohashi, Y., Noda, M., Kadowaki, T., & J-DOIT3 Study Group. (2017). Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): An open-label, randomised controlled trial. The Lancet Diabetes & Endocrinology, 5(12), 951–964. https://doi.org/10.1016/S2213-8587(17)30327-3
  8. Fan, W., Song, Y., Inzucchi, S. E., Sperling, L., Kosiborod, M., Plutzky, J., & Wong, N. D. (2019). Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 21(5), 1121–1127. https://doi.org/10.1111/dom.13625
  9. Chan, J. C. N., Lim, L. L., Luk, A. O. Y., Ozaki, R., Kong, A. P. S., Ma, R. C. W., & So, W. Y. (2019). From Hong Kong Diabetes Register to JADE program to RAMP-DM for data-driven actions. Diabetes Care, 42(11), 2022–2031. https://doi.org/10.2337/dci19-0003
  10. National Glycohemoglobin Standardization Program. (2010). NGSP website. http://www.ngsp.org/index.asp
  11. Luk, A. O., Li, X., Zhang, Y., Guo, X. H., Yu, W., Chow, C. C., ... JADE Study Group. (2016). Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. Diabetic Medicine, 33(9), 1230–1239. https://doi.org/10.1111/dme.13014
  12. International Diabetes Federation. (2019). IDF Diabetes Atlas (9th ed.). International Diabetes Federation. https://www.diabetesatlas.org
  13. Sonthon, P., Promthet, S., Changsirikulchai, S., Rangsin, R., Thinkhamrop, B., & Hurst, C. (2017). The impact of the quality of care and other factors on progression of chronic kidney disease in Thai patients with type 2 diabetes mellitus: A nationwide cohort study. PLoS One, 12(7), Article e0180977. https://doi.org/10.1371/journal.pone.0180977
  14. Luk, A. O. Y., Hui, E. M. T., Sin, M. C., Lau, E. S. H., Yang, X., Chow, C. C., Ma, R. C. W., So, W. Y., & Chan, J. C. N. (2017). Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes: The Hong Kong Diabetes Database. Diabetes Care, 40(7), 928–935. https://doi.org/10.2337/dc16-2354
  15. Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., & Gregg, E. W. (2019). Global trends in diabetes complications: A review of current evidence. *Diabetologia“, 62(1), 3–16. https://doi.org/10.1007/s00125-018-4711-2
  16. Wu, H., Lau, E. S. H., Ma, R. C. W., Kong, A. P. S., So, W. Y., Luk, A. O. Y., & Chan, J. C. N. (2020). Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001–2016: A retrospective cohort study. Diabetologia, 63(4), 757–766. https://doi.org/10.1007/s00125-019-05074-7
  17. Lim, L. L., Lau, E. S. H., Ozaki, R., Luk, A. O. Y., Kong, A. P. S., Ma, R. C. W., So, W. Y., & Chan, J. C. N. (2020). Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE program: A retrospective cohort analysis. PLoS Medicine, 17(10), Article e1003367. https://doi.org/10.1371/journal.pmed.1003367
  18. Chan, J. C. N., Sui, Y., Oldenburg, B., Zhang, Y., Yeung, C. Y., Ross, I. S., ... JADE and PEARL Project Team. (2014). Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: A randomized clinical trial. JAMA Internal Medicine, 174(6), 972–981. https://doi.org/10.1001/jamainternmed.2014.655
  19. Yin, J., Luk, A., Wong, R., Zhang, Y., Ozaki, R., Kong, A. P., So, W. Y., & Chan, J. C. N. (2017). Regular mailing of personalized feedback reports improves glycemic control in diabetes: A randomized controlled trial. Journal of Diabetes, 9(5), 536–538. https://doi.org/10.1111/1753-0407.12527
  20. Tutino, G. E., Yang, W. Y., Li, X., Luk, A. O., Kwong, S., ... China JADE Study Group. (2017). A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with type 2 diabetes. Diabetic Medicine, 34(3), 440–450. https://doi.org/10.1111/dme.13164
  21. Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., & Sabatine, M. S. (2019). Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation, 139(17), 2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868
  22. Wong, R. Y. M. (2010, October 18). A randomized study to evaluate the effectiveness of a treat to target clinic led by nurse consultant in high risk patients with type 2 diabetes [Paper presentation]. 8th International Diabetes Federation Western Pacific Region Congress, Busan, Korea.
  23. Chan, J. C., So, W. Y., Yeung, C. Y., Ko, G. T., Lau, K. P., Tsang, M. W., ... SURE Study Group. (2009). Effects of structured versus usual care on renal endpoint in type 2 diabetes: The SURE study: A randomized multicenter translational study. Diabetes Care, 32(6), 977–982. https://doi.org/10.2337/dc08-1908
  24. Kong, A. P. S., Yang, X., Ko, G. T. C., So, W. Y., Chow, C. C., Tong, P. C. Y., & Chan, J. C. N. (2007). Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care, 30(4), 953–959. https://doi.org/10.2337/dc06-2443
  25. Zuo, H. J., Wang, W. H., Deng, L. Q., & Su, J. L. (2018). Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension, 12(2), 128–134. https://doi.org/10.1016/j.jash.2017.12.006
  26. van Buuren, S., & Groothuis-Oudshoorn, K. (2011). mice: Multivariate imputation by chained equations in R. Journal of Statistical Software, 45(3), 1–67. https://doi.org/10.18637/jss.v045.i03
  27. The World Bank. (2019). World Bank country and lending groups. The World Bank Group. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
  28. Chan, J. C. (2011). What can we learn from the recent blood glucose lowering megatrials? Journal of Diabetes Investigation, 2(1), 1–5. https://doi.org/10.1111/j.2404-1124.2010.00063.x
  29. Wan, E. Y. F., Fung, C. S. C., Jiao, F. F., Yu, E. Y. T., Chin, W. Y., Fong, D. Y. T., Wong, C. K. H., Chan, K. H., & Lam, C. L. K. (2018). Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service uses—A population-based and propensity-matched cohort study. Diabetes Care, 41(1), 49–59. https://doi.org/10.2337/dc17-0426
  30. Gaede, P., Lund-Andersen, H., Parving, H. H., & Pedersen, O. (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine, 358(6), 580–591. https://doi.org/10.1056/NEJMoa0706245
  31. Chan, J. C. N., Lim, L. L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., ... Commission Members. (2021). The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives. The Lancet, 396(10267), 2019–2082. https://doi.org/10.1016/S0140-6736(20)32374-6
  32. Organisation for Economic Co-operation and Development, & World Health Organization. (2018). Health at a glance: Asia/Pacific 2018: Measuring progress towards universal health coverage. OECD Publishing. https://www.oecd.org/health/health-at-a-glance-asia-pacific-23054964.htm
  33. Shanafelt, T., Goh, J., & Sinsky, C. (2017). The business case for investing in physician well-being. JAMA Internal Medicine, 177(12), 1826–1832. https://doi.org/10.1001/jamainternmed.2017.4340
  34. Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Tall, B., Cherney, D. Z. I., McGuire, D. K., & VERTIS CV Investigators. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine, 383(15), 1425–1435. https://doi.org/10.1056/NEJMoa2004967
  35. Yeung, R. O., Zhang, Y., Luk, A., Yang, W., Mansour, A., ... JADE programme. (2014). Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): A cross-sectional study of a prospective cohort. The Lancet Diabetes & Endocrinology, 2(12), 935–943. https://doi.org/10.1016/S2213-8587(14)70137-8

Cite

Lim, L. L., Lau, E. S. H., Fu, A. W. C., Ray, S., Hung, Y. J., Tan, A. T. B., Chamnan, P., Sheu, W. H. H., Chawla, M. S., Chia, Y. C., Chuang, L. M., Nguyen, D. C., Sosale, A., Saboo, B. D., Phadke, U., Kesavadev, J., Goh, S. Y., Gera, N., Huyen Vu, T. T., Ma, R. C. W., … Asia-Pacific JADE Study Group (2021). Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients With Type 2 Diabetes in the Asia-Pacific Region: The JADE Program Randomized Clinical Trial. JAMA network open, 4(4), e217557. https://doi.org/10.1001/jamanetworkopen.2021.7557

COPY CITATION Copied!
DOWNLOAD FULL PDF VIEW RESEARCH HERE